Assessing Scholar Rock (SRRK) Valuation After Recent Share Pullback And Conflicting P/B And DCF Signals

Simply Wall St

Tue, February 24, 2026 at 11:11 AM GMT+9 4 min read

In this article:

SRRK

-2.06%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

With no single headline event driving attention today, Scholar Rock Holding (SRRK) is back on watch for many investors as they reassess recent share performance, clinical focus, and the company’s current financial profile.

See our latest analysis for Scholar Rock Holding.

Scholar Rock Holding’s share price has pulled back 2.06% over the last day to US$47.01. The 30 day share price return of 6.14% and one year total shareholder return of 26.51% sit within a much stronger three year total shareholder return that is more than 4x.

If you are watching biotech momentum like this, it may also be a good time to scan a focused list of 27 healthcare AI stocks as another way to find potential opportunities in the space.

With shares up 26.51% over the past year and trading close to the average analyst price target, the key question is whether Scholar Rock is still undervalued or if the market is already pricing in its future growth.

Preferred Price-to-Book Multiple of 19.6x: Is It Justified?

Scholar Rock is currently trading at a P/B of 19.6x, which our checks describe as good value against its peer group average of 24.8x, but expensive relative to the broader US biotech industry at 2.6x.

The P/B ratio compares the company’s market value to its book value, which can be a useful yardstick for asset heavy or early stage biotech names that do not yet have meaningful earnings. In this case, the market is assigning a premium to Scholar Rock’s balance sheet, even though the company is still unprofitable and reported a loss of $353.428m and less than $1m in revenue.

Compared with closer peers, a 19.6x P/B is below the 24.8x average, which suggests investors are not paying the top end of sector valuations for this stock. However, that same 19.6x stands very high against the US biotech industry’s 2.6x average, so the market is clearly pricing Scholar Rock well above the broader group on this metric.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 19.6x (OVERVALUED)

DCF Signal Points To A Very Large Discount

Alongside the P/B view, the SWS DCF model flags a much lower implied value gap, with Scholar Rock at $47.01 versus an estimated future cash flow value of $174.36, described as trading at 73% below that estimate.

The DCF model works by estimating future cash flows and then discounting them back to today using a required return, which produces a single present value per share. For a company like Scholar Rock, with very limited current revenue and ongoing losses, that type of model leans heavily on assumptions about future growth, timing of potential cash inflows and the cost of capital.

繼續閱讀  

Those inputs, along with the company’s early stage clinical portfolio and forecast revenue growth profile, help explain why the DCF output can differ sharply from snapshot multiples like P/B that are anchored to today’s balance sheet and market pricing.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF Fair value of $174.36 (UNDERVALUED)

However, you also need to weigh real risks, including ongoing clinical trial uncertainty and the company’s current loss of US$353.428m on minimal reported revenue.

Find out about the key risks to this Scholar Rock Holding narrative.

Another Way To Look At Scholar Rock

The SWS DCF model presents a very different view compared with the rich P/B ratio. With a fair value estimate of $174.36 versus the current $47.01, it suggests the shares may be significantly undervalued. This raises the question: is the market being too cautious, or is the model too optimistic?

Look into how the SWS DCF model arrives at its fair value.

SRRK Discounted Cash Flow as at Feb 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Scholar Rock Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 56 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals or a clear setup: either way, it is worth checking the full picture for yourself and doing it sooner rather than later, including our breakdown of 2 key rewards and 3 important warning signs so you can weigh the trade off in your own way.

Looking for more investment ideas?

If Scholar Rock has caught your eye, do not stop here. Broaden your watchlist now so you are not left reacting after the next move.

Target quality at a discount by scanning our 56 high quality undervalued stocks to see which companies currently trade below our assessment of their worth.

Prioritise resilience with the 79 resilient stocks with low risk scores to focus on businesses that score well on our risk checks.

Hunt for future standouts with the screener containing 23 high quality undiscovered gems and spot companies that sit off the usual radar but pass solid fundamental screens.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include SRRK.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

條款 及 私隱政策

Privacy Dashboard

More Info